 CINCINNATI, Feb. 23, 2021 GLOBE NEWSWIRE -- Meridian Bioscience, Inc. NASDAQ: VIVO, a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization EUA with the U.S. Food and Drug Administration FDA for the SARS-CoV-2 molecular diagnostic test on its Revogene platform. 